A scientific article on Double Bond Pharmaceutical’s investigation into how MGMT status affects the effectiveness of treatment with Temodex has been accepted for publication in the journal Neoplasma.
“The information from the survey provides important understanding into the therapeutic value of Temodex, and we are pleased to publish our findings about Temodex and MGMT in a high-quality scientific journal. Thanks to close cooperation with all involved parties we have been able to accomplish this very quickly. “, – says Igor Lokot, CEO of Double Bond Pharmaceutical. “This survey confirms Temodex therapeutic value and reinforces our negotiating positions regarding licensing of the product, and may double our future market for treatment of brain cancer.”
“Neoplasm is a well-known, expert-reviewed scientific journal, and it is an honor for us to have our article accepted for publishing with them,” commented Iulia Karlsson, Head of Biomarker Development at Double Bond Pharmaceutical. “We will follow up our findings from the MGMT study in the upcoming clinical trial for SI053 to see if the trend holds for all types of brain cancer treated with Temodex. That will give us the opportunity to study a larger group of patients and thus provide a broader basis for our results. ”
More about Neoplasma
The journal Neoplasma publishes articles on experimental and clinical oncology and cancer epidemiology.
More about the MGMT pilot survey
More about MGMT
Epigenetic silencing of the MGMT (O6-methylguanine–DNA methyltransferase) DNA-repair gene by promoter methylation compromises DNA repair and has been associated with longer survival in patients with glioblastoma who receive alkylating agents.
Full Company Name:
Double Bond Pharmaceutical International AB (publ)
Stock short name:
Share ISIN code:
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.